Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hisamitsu Launches Japan PIII of Microneedle-Based Topical Drug
August 5, 2025
- Kyowa Kirin CEO Highlights Resource Shift toward Innovative Drugs in Japan
August 4, 2025
- Rohto Pairs with Taiwan’s Formosa to Fuel Regenerative Medicine Business
August 4, 2025
- Leqembi Maintains Benefits in Early Alzheimer’s after 4 Years of Treatment
August 1, 2025
- Kyowa Kirin Sees Flat H1 Revenue as Japan Slump Offsets Overseas Gains
August 1, 2025
- Otsuka Accelerates Pipeline Investment Centered on “Next 8” as Growth Drivers
August 1, 2025
- Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
August 1, 2025
- Daiichi Sankyo Plays Down Tariff Impact for FY2025, Eyes US Production Boost
August 1, 2025
- Leqembi’s April-June Sales at 23.1 Billion Yen: Eisai
August 1, 2025
- Nihon Chouzai to Go Private through Tender Offer Backed by Advantage Partners
August 1, 2025
- Takeda Sees Limited Tariff Exposure as US Remains Strategic Priority
July 31, 2025
- Astellas Assembles Task Team to Assess US Tariff Risks
July 31, 2025
- Kissei Licenses Thyroid Eye Disease Candidates from Viridian
July 31, 2025
- Novo Japan Files Sogroya for SGA-Related and Noonan Syndrome Short Stature
July 31, 2025
- AstraZeneca, Japanese Circulation Association Join Hands to Tackle Cardiovascular Disease
July 31, 2025
- Lilly Launches Higher-Dose Trulicity in Japan for Type 2 Diabetes
July 31, 2025
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
- Gene Therapy Deaths Spur Strategic Rethink among Biotechs, Merck Exec Notes Investor Caution
July 30, 2025
- Otsuka Ups H1 Earnings Outlook on Rexulti, Other Global Brands
July 30, 2025
- Lenvima Bolsters Label for HCC in China: Eisai
July 30, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…